Zuoli Pharmaceutical said during institutional research that Lingyi Biotech's Parkinson Line LY-N001 research work is continuing to advance, and the main pre-clinical research work has now been completed. The pipeline targets patients with the Parkinson subtype associated with the GBA1 gene mutation. The future goal is to carry out IND declarations between China and the US and carry out clinical research and global market layout. Ling Yi Biotech is an innovative drug research and development enterprise focusing on the origin of single-gene genetic diseases. It is positioned to develop gene therapy drugs with differentiated advantages. The company increased its capital to Lingyi Biotech by 20 million yuan in April 2025.

Zhitongcaijing · 09/07/2025 01:17
Zuoli Pharmaceutical said during institutional research that Lingyi Biotech's Parkinson Line LY-N001 research work is continuing to advance, and the main pre-clinical research work has now been completed. The pipeline targets patients with the Parkinson subtype associated with the GBA1 gene mutation. The future goal is to carry out IND declarations between China and the US and carry out clinical research and global market layout. Ling Yi Biotech is an innovative drug research and development enterprise focusing on the origin of single-gene genetic diseases. It is positioned to develop gene therapy drugs with differentiated advantages. The company increased its capital to Lingyi Biotech by 20 million yuan in April 2025.